New drug FXB0871 takes on advanced cancers in first human trial

This early-phase trial tests an experimental drug called FXB0871 in about 138 adults with advanced solid tumors, including non-small cell lung cancer and liver cancer, that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and second, checking if the drug can shrink tumors. The goal is to control the disease, not cure it, and participants will be closely monitored for side effects.